Experta®

Apixaban

2.5mg & 5mg film coated-tablets

Patient Card

Carry this card with you all times

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

Information for patients

- Take Experta® regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
- Do not stop taking Experta® without talking to your doctor, as you are at risk of suffering from a stroke or other complications.
- Experta® helps to thin your blood. However, this may increase your risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-colored stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood
- If the bleeding does not stop on its own, seek medical attention immediately.
- If you need surgery, inform your doctor that you are taking Experta®.

Experta®
Apixaban
2.5mg & 5mg film coated-tablets

I am under anticoagulation treatment with Experta® to prevent blood clots

Information for healthcare professionals

- Experta® is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Experta® may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Experta® does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) - see SmPC.
- An agent to reverse the anti-factor Xa activity of apixaban is available.

Experta®
Apixaban
2.5mg & 5mg film coated-tablets

Please fill the below section or ask your Doctor to do it

Name of the patient: _____

Date of Birth: _____

Indication: _____

Dose: _____mg Twice Daily_____

Other Medicine / Condition: _____

_____

In case of emergency, please notify:

Doctor's name: _____

Doctor's Telephone Number:_____

* This document has been reviewed and approved by Saudi Food and Drug Authority (SFDA)

Any suspected adverse events should be reported to the national spontaneous reporting system according to the national regulations.

National Pharmacovigilance Center at Saudi Food and Drug Authority (SFDA):
Website: https://ade.sfda.gov.sa
Email to: npc.drug@sfda.sa
Direct number: 19999

Or Pharmacovigilance Department in SPIMACO
Email: GPV@spimaco.sa
Direct number: +966 11 252 3393
Online: http://spimaco.com.sa/pharmacovigilance/form